Literature DB >> 1924135

The importance of surface charge in the optimization of antigen-adjuvant interactions.

P M Callahan1, A L Shorter, S L Hem.   

Abstract

The adsorptive behavior of the recombinant malarial antigens R32tet32, R32NS181 and NS181V20 to aluminum hydroxide and aluminum phosphate gels was studied as a function of pH and buffer ions. The Plasmodium falciparum antigen, R32NS181, and the P. vivax antigen, NS181V20, with isoelectric points (pI) of 5.9 and 5.5, respectively, adsorbed readily to the positively charged boehmite form of aluminum hydroxide gel. These two antigens displayed reversible, linear adsorption behavior in the pH range 5-9, with maximal adsorption observed at the lowest pH studied. The addition of acetate buffer ions had little effect on adsorption, while the presence of phosphate decreased adsorption for R32NS181 and NS181V20 by 25 and 40% respectively. The adsorptive behavior of these two antigens with the negatively charged adjuvant, aluminum phosphate, was markedly decreased. The converse situation was observed with the R32tet32 antigen, whose pI is estimated to be 12.8. There was minimal interaction of this antigen with aluminum hydroxide gel except in the presence of phosphate counter ions and significant, nonreversible adsorption with aluminum phosphate gel. Enhanced adsorption of R32tet32 to aluminum hydroxide gel in the presence of phosphate is suggested to be the result of a covalent bond between a surface aluminum and a phosphate anion that modifies the surface charge of the aluminum hydroxide gel. These results indicate that the role of complementary surface charges, both for the ionization state of the protein and for the aluminum adjuvants, is the key in optimizing conditions for significant antigen-adjuvant interactions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924135     DOI: 10.1023/a:1015843210358

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Desorption of porcine parvovirus from aluminum hydroxide adjuvant with subsequent viral immunoassay or hemagglutination assay.

Authors:  J Katz
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

Review 2.  Future prospects for vaccine adjuvants.

Authors:  H S Warren; L A Chedid
Journal:  Crit Rev Immunol       Date:  1988       Impact factor: 2.214

Review 3.  Proteins at interfaces.

Authors:  F Macritchie
Journal:  Adv Protein Chem       Date:  1978

Review 4.  Aluminium compounds as adjuvants for vaccines and toxoids in man: a review.

Authors:  M A Aprile; A C Wardlaw
Journal:  Can J Public Health       Date:  1966-08

5.  Assay, purification and characterization of a recombinant malaria circumsporozoite fusion protein by high-performance liquid chromatography.

Authors:  G Folena-Wasserman; R Inacker; J Rosenbloom
Journal:  J Chromatogr       Date:  1987-12-18

Review 6.  Current status of immunological adjuvants.

Authors:  H S Warren; F R Vogel; L A Chedid
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

7.  Adsorption of pepsin by aluminum hydroxide II: Pepsin inactivation.

Authors:  R J Sepelyak; J R Feldkamp; F E Regnier; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1984-11       Impact factor: 3.534

8.  Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines.

Authors:  S L Hem; J L White
Journal:  J Parenter Sci Technol       Date:  1984 Jan-Feb

9.  Aluminum compounds used as adjuvants in vaccines.

Authors:  S Shirodkar; R L Hutchinson; D L Perry; J L White; S L Hem
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

10.  Adsorption of pepsin by aluminum hydroxide I: Adsorption mechanism.

Authors:  R J Sepelyak; J R Feldkamp; T E Moody; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1984-11       Impact factor: 3.534

View more
  8 in total

1.  Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.

Authors:  R P Weissburg; P W Berman; J L Cleland; D Eastman; F Farina; S Frie; A Lim; J Mordenti; T T Nguyen; M R Peterson
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

Review 2.  Immunopotentiation and delivery systems for antigens for single-step immunization: recent trends and progress.

Authors:  M Z Khan; J P Opdebeeck; I G Tucker
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

3.  Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.

Authors:  Erman Tritama; Catur Riani; Indra Rudiansyah; Arip Hidayat; Siti Azizah Kharisnaeni; Debbie Sofie Retnoningrum
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

Review 4.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

Authors:  Manmohan Singh; James Chesko; Jina Kazzaz; Mildred Ugozzoli; Elaine Kan; Indresh Srivastava; Derek T O'Hagan
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

6.  Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine.

Authors:  Amber L Clausi; Andrea Morin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

Review 7.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

Authors:  Harm HogenEsch; Derek T O'Hagan; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-10-10       Impact factor: 7.344

8.  Silica-based cationic bilayers as immunoadjuvants.

Authors:  Nilton Lincopan; Mariana Ra Santana; Eliana Faquim-Mauro; Maria Helena B da Costa; Ana M Carmona-Ribeiro
Journal:  BMC Biotechnol       Date:  2009-01-19       Impact factor: 2.563

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.